NOVARTIND vs RUBICON: Stock Comparison
RUBICON RESEARCH is the larger company by market capitalisation. NOVARTIS INDIA shows a lower P/E, lower leverage and a higher net margin, while RUBICON RESEARCH shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
NOVARTIND leads 6; RUBICON leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | NOVARTIND | RUBICON |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | NOVARTIND | RUBICON |
|---|---|---|
| Live Price | ₹2,135.1 | ₹1,791.1 |
| Day Change | 7% | 1.38% |
| Volume | 1.14 L | 1.17 L |
| 52-Week High | ₹2,588.8 | ₹1,899 |
| 52-Week Low | ₹950 | ₹570.75 |
| Distance from 52W High | -17.53% | -5.68% |
Valuation
| Metric | NOVARTIND | RUBICON |
|---|---|---|
| Market Cap | ₹5,286 Cr | ₹29,632 Cr |
| P/E Ratio | 50.32x | 102.12x |
| P/B Ratio | 6.02x | 22.84x |
| EPS | ₹13.05 | ₹4.99 |
| Book Value | ₹331.23 | ₹77.93 |
| Dividend Yield | 0% | 0.08% |
Growth
| Metric | NOVARTIND | RUBICON |
|---|---|---|
| Revenue Growth (TTM YoY) | 8% | 43.5% |
| EPS Growth (TTM YoY) | -13.8% | 96.6% |
| Qtr Sales Growth | -70.7% | -19.95% |
| Qtr Profit Growth | -65.43% | -2.75% |
Profitability & Leverage
| Metric | NOVARTIND | RUBICON |
|---|---|---|
| ROE | 11.39% | 19.14% |
| ROCE | 14.33% | 20.49% |
| Net Margin | 26.3% | 13.48% |
| Operating Margin | 36.95% | 20.68% |
| Debt to Equity | 0x | 0.2x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | NOVARTIND | RUBICON |
|---|---|---|
| Promoter Holding | 0% | 23.93%▼ 0.04 pp |
| FII Holding | 0.16%▼ 0.01 pp | 7.52%▼ 0.02 pp |
| DII Holding | 1.36%▲ 0.83 pp | 9.43%▼ 0.59 pp |
| Public Holding | 27.8%▼ 0.81 pp | 23.3%▲ 0.72 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NOVARTIS INDIA and RUBICON RESEARCH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.